Richard Haubrich

13.0k total citations · 2 hit papers
184 papers, 8.8k citations indexed

About

Richard Haubrich is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Richard Haubrich has authored 184 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Infectious Diseases, 116 papers in Virology and 38 papers in Epidemiology. Recurrent topics in Richard Haubrich's work include HIV Research and Treatment (116 papers), HIV/AIDS drug development and treatment (111 papers) and HIV/AIDS Research and Interventions (99 papers). Richard Haubrich is often cited by papers focused on HIV Research and Treatment (116 papers), HIV/AIDS drug development and treatment (111 papers) and HIV/AIDS Research and Interventions (99 papers). Richard Haubrich collaborates with scholars based in United States, United Kingdom and France. Richard Haubrich's co-authors include Carol A. Kemper, Michael M. Lederman, David Katzenstein, Jill Blumenthal, Michael P. Dubé, J. Allen McCutchan, Diane V. Havlir, Martin Hirsch, Sonia Jain and Sharon A. Riddler and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Richard Haubrich

174 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter

1996 768 citations David Katzenstein, Michael D. Hughes et al. profile →
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

2008 500 citations Sharon A. Riddler, Richard Haubrich et al. profile →

Peers

Countries citing papers authored by Richard Haubrich

Since Specialization

Citations

This map shows the geographic impact of Richard Haubrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Haubrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Haubrich more than expected).

Fields of papers citing papers by Richard Haubrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Haubrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Haubrich. The network helps show where Richard Haubrich may publish in the future.

Co-authorship network of co-authors of Richard Haubrich

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Haubrich. A scholar is included among the top collaborators of Richard Haubrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Haubrich. Richard Haubrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen 2024 ·Open Forum Infectious Diseases ·Essy Mozaffari, Aastha Chandak, (unknown), André C. Kalil, Heng Jiang, Eunyoung Lee, (unknown), Mark Thrun, Mark Berry, Richard Haubrich, Robert Gottlieb	6
2	Prevalence and Factors Associated With Patient–Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced Therapy 2024 ·ACR Open Rheumatology ·Jeffrey R. Curtis, Robert R. McLean, (unknown), Rachel H. Mackey, Page C. Moore, Richard Haubrich, Jeffrey D. Greenberg, (unknown)	0
3	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort 2021 ·Clinical Infectious Diseases ·Essy Mozaffari, Aastha Chandak, (unknown), Shuting Liang, Mark Thrun, Robert Gottlieb, Daniel R. Kuritzkes, Paul E. Sax, David A. Wohl, Roman Casciano, Paul Hodgkins, Richard Haubrich	79
4	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States 2021 ·Open Forum Infectious Diseases ·Essy Mozaffari, Aastha Chandak, (unknown), Shuting Liang, Julie Gayle, Mark Thrun, Robert Gottlieb, Daniel R. Kuritzkes, Paul E. Sax, David A. Wohl, Roman Casciano, Paul Hodgkins, Richard Haubrich	3
5	PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study 2021 ·Value in Health ·Essy Mozaffari, (unknown), (unknown), (unknown), Richard Haubrich, Mark Thrun, P. Hodgkins	1
6	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens 2020 ·PLoS ONE ·Gregory Huhn, Moti Ramgopal, Mamta K. Jain, Federico Hinestrosa, David M. Asmuth, Jihad Slim, Deborah Goldstein, (unknown), (unknown), Shuping Jiang, Stephanie Cox, Moupali Das, (unknown), David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard Haubrich	5
7	Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men 2019 ·AIDS Patient Care and STDs ·Jill Blumenthal, David J. Moore, Sonia Jain, Xiaoying Sun, Eric Ellorin, Katya Corado, Martin Hoenigl, Michael P. Dubé, Richard Haubrich, Sheldon Morris, (unknown)	5
8	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants 2017 ·The Journal of Infectious Diseases ·Katie R. Mollan, Camlin Tierney, Jacklyn N. Hellwege, Joseph J. Eron, Michael G. Hudgens, Roy M. Gulick, Richard Haubrich, Paul E. Sax, Thomas Campbell, Eric S. Daar, Kevin R. Robertson, (unknown), Qing Ma, Digna R. Velez Edwards, David W. Haas	25
9	Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression 2014 ·Antiviral Research ·Nadejda Beliakova‐Bethell, Sonia Jain, Christopher H. Woelk, Mallory D. Witt, Xiaoying Sun, Steven M. Lada, Celsa A. Spina, Miguel Goicoechea, Steffney E. Rought, Richard Haubrich, Michael P. Dubé	11
10	Biceps Skin-fold Thickness May Detect and Predict Early Lipoatrophy in HIV-infected Children 2012 ·The Pediatric Infectious Disease Journal ·Steve Innes, (unknown), Mark F. Cotton, Ekkehard Werner Zöllner, Richard Haubrich, Hartwig Klinker, Xiaoying Sun, Sonia Jain, (unknown), (unknown), (unknown), Helena Rabie, Sara H. Browne	4
11	Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jessica H. Brehm, Christina M. Lalama, Michael D. Hughes, Richard Haubrich, Sharon A. Riddler, Nicolas Sluis‐Cremer, John W. Mellors	3
12	Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data 2011 ·Cost Effectiveness and Resource Allocation ·Kit N. Simpson, (unknown), Robert W. Baran, Kevin W. Garren, Sharon A. Riddler, Menaka Bhor, Richard Haubrich	7
13	Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients 2010 ·AIDS ·Miguel Goicoechea, Sonia Jain, (unknown), Carol A. Kemper, Eric S. Daar, Catherine Diamond, Belinda Ha, John F. Flaherty, Shelly Sun, Douglas D. Richman, Stan G. Louie, Richard Haubrich	13
14	TMC125 Safety and Tolerability in Treatment-Experienced, HIV Infected Patients - Pooled DUET Trial Data 2007 ·Richard Haubrich	2
15	Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients 2007 ·AIDS ·Richard Haubrich, (unknown), Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag, Ben Van Baelen, Éric Lefebvre	96
16	Improved Virologic Response in Three-Class Experienced Patients When an Active Boosted Protease Inhibitor is Used with Enfuvirtide (ENF) 2005 ·Richard Haubrich	6
17	Clinical Utility of Resistance Testing: Retrospective and Prospective Data Supporting Use and Current Recommendations 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Richard Haubrich, Lisa M. Demeter	47
18	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase 2000 ·AIDS ·Michael M. Lederman, Ray A. McKinnis, Dennis Kelleher, Amy Cutrell, John W. Mellors, (unknown), Elizabeth Cooney, David W. Haas, Richard Haubrich, James Stanford, James Horton, Alan Landay, William Spreen	69
19	Virologic and CD4 ⁺ Cell Responses to New Nucleoside Regimens: Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection 2000 ·AIDS Research and Human Retroviruses ·David Katzenstein, H. Hughes, Mary Albrecht, S. Hammer, M F Para, Robert L. Murphy, Hernán Valdez, Richard Haubrich, Saou-Hsing Liou	11
20	Human Immunodeficiency Virus Replication in AIDS Patients withMycobacterium aviumComplex Bacteremia: A Case Control Study 1998 ·The Journal of Infectious Diseases ·Diane V. Havlir, Richard Haubrich, Jimmy Hwang, Michael W. Dunne, Judith S. Currier, Donald N. Forthal, Francesca J. Torriani, Douglas D. Richman, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact